Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress

Ads

You May Also Like

Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine

Phase I study demonstrates matching pharmacokinetic (PK), pharmacodynamic (PD), safety and immunogenicity profiles of ...

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

--CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell ...

Targovax granted US Patent for mutant-RAS neoantigen platform lead products

Extends IP protection of TG01 and TG02 until 06.05.2034Oslo, 25 September 2017: Targovax ASA ...